Goldman Sachs downgraded contract research organizations Icon Public Limited (NASDAQ:ICLR) and Charles River Laboratories (NYSE:CRL) to Neutral from Buy on Friday, citing a challenging near-term ...

We purchased shares of Icon in March 2024 for ~$323.00 per share. Why did we sell our ICLR position and move on? Click here ...

today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization (CRO) powered by healthcare intelligence, will immediately begin utilizing Medidata Clinical Data ...

For more information, visit: www.3ds.com. About ICON plc ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical ...

For more information, visit: www.3ds.com. About ICON plc ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research ...

today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization (CRO) powered by healthcare intelligence, will immediately begin utilizing Medidata Clinical Data Studio on ...